Initial Treatment for Lupus Pericarditis

First-Line Therapy

• The European Society of Cardiology recommends starting with either aspirin (750-1000 mg every 8 hours) or ibuprofen (600 mg every 8 hours) for 1-2 weeks with gastroprotection 2, 3
• Colchicine should be added as part of first-line therapy at weight-adjusted doses: 0.5 mg once daily if <70 kg 4 and 0.5 mg twice daily if ≥70 kg 2, 4

Treatment Algorithm

• Initial assessment should evaluate for high-risk features (fever >38°C, large effusion >20mm, tamponade, or failure to respond to NSAIDs within 7 days) 2
• For non-high-risk cases, outpatient management with NSAIDs plus colchicine is recommended 2, 3
• Monitor response using CRP to guide treatment length and assess response 4

Second-Line Therapy

• Low-dose prednisone (0.2-0.5 mg/kg/day) should be considered only when NSAIDs/colchicine are contraindicated or first-line therapy fails 3
• Corticosteroids should NOT be first-line therapy as they increase risk of chronicity and recurrence 4

Special Considerations for Lupus Pericarditis

• The risk of developing constrictive pericarditis is intermediate (2-5%) for autoimmune etiologies like lupus compared to idiopathic causes (<1%) 1, 4
• For lupus patients with pericarditis associated with other SLE manifestations, treatment should address the underlying disease activity 5

Monitoring and Follow-up

• Treatment should continue until complete symptom resolution and normalization of CRP 2, 3
• Exercise restriction should be considered until symptoms resolve and diagnostic tests normalize 4
• Monitor for recurrence, which occurs in 15-30% of patients with acute pericarditis not treated with colchicine 4

Pitfalls to Avoid

• Inadequate treatment of the first episode is a common cause of recurrence 4
• Premature discontinuation of anti-inflammatory therapy before complete resolution of symptoms and normalization of inflammatory markers 2, 3
• Overreliance on corticosteroids, which may provide rapid symptom control but increase risk of chronicity and recurrence 4
• Failure to add colchicine to NSAIDs, which significantly reduces recurrence rates 1